Oxford BioSignals gains
FDA clearance to market BioSomnia
A single channel portable sleep monitor
 Oxford
BioSignals limited are pleased to announce the
BioSomnia portable sleep system has gains FDA clearance
to market BioSomnia.
Developed from leading edge neural network technology,
BioSomnia is the first single EEG channel sleep system
to provide objective information on the quantity
and quality of sleep.
BioSomnia is a lightweight, battery powered portable
monitor processing a single channel of EEG overnight.
BioSomnia is easy to use, with a choice of electrode
montages below the hairline to simplify patient hook
up.
BioSomnia analyses the EEG signal in real time and
easy to use rapid report generator software displays
information on sleep latency, duration, fragmentation
and Microarousals.
Experts agree that effective treatment of insomnia
requires good diagnosis, yet doctors lack the means
to measure sleep easily and objectively in the patient’s
home environment. BioSomnia can assist diagnosis,
guide therapy and help evaluate efficacy of treatments.
BioSomnia offers a cost effective sleep analysis
tool for laboratory or home studies.
First shipments of BioSomnia have begun in November
2002 to USA ad Europe.
Oxford BioSignals, whose headquarters are at Oxford,
UK, are pioneers in bringing neural network technology
to automatic sleep analysis.
For further information contact:
Wayne Edwards, International sales manager, +44 1865 336170,
wayne.Edwards@oxford-biosignals.com |
